Suzhou Highfine Biotech (301393.SZ): Employee strategic placement management plan intends to reduce holdings of company shares by no more than 0.5%
Haofan Biology (301393.SZ) announced that shareholder Minsheng Securities - CITIC Bank - Minsheng Securities Haofan Biology Strategic Placement 1 Collective Asset Management Plan (referred to as "Employee Strategic Placement Asset Management Plan") plans to reduce the company's shares by no more than 541,800 shares (0.50% of the total share capital of the company) through centralized bidding or block trading within 3 months after the date of this announcement, starting from 15 trading days after the disclosure of this announcement.
Suzhou Highfine Biotech (301393.SZ) announced that shareholder MinSheng Securities-CITIC BANK-MinSheng Securities Suzhou Highfine Biotech Strategic Placement No. 1 Collective Asset Management Plan (referred to as the "Employee Strategic Placement Asset Management Plan") plans to reduce its holdings of the company's shares through centralized bidding or block trading within 3 months after 15 trading days from the disclosure of this announcement, not exceeding 541,800 shares (0.50% of the company's total share capital).
Related Articles
PW MEDTECH (01358) spent about HK$400,000 to repurchase 344,000 shares on May 27th.
A-share announcement highlights | Kweichow Moutai (600519.SH): Share repurchase completed, spent 3 billion yuan to repurchase 2.1886 million shares.
Kuaishou: It is expected that the return on equity will increase to about 4% by 2026, and the full-year target of positive free cash flow will be maintained.
PW MEDTECH (01358) spent about HK$400,000 to repurchase 344,000 shares on May 27th.
A-share announcement highlights | Kweichow Moutai (600519.SH): Share repurchase completed, spent 3 billion yuan to repurchase 2.1886 million shares.
Kuaishou: It is expected that the return on equity will increase to about 4% by 2026, and the full-year target of positive free cash flow will be maintained.
